The big picture on nanomedicine: the state of investigational and approved nanomedicine products

被引:799
作者
Etheridge, Michael L. [2 ,3 ]
Campbell, Stephen A. [4 ]
Erdman, Arthur G. [3 ]
Haynes, Christy L. [5 ]
Wolf, Susan M. [6 ]
McCullough, Jeffrey [1 ]
机构
[1] Univ Minnesota, Inst Engn Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Dept Mech Engn, Minneapolis, MN 55455 USA
[4] Univ Minnesota, Dept Elect & Comp Engn, Minneapolis, MN 55455 USA
[5] Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA
[6] Univ Minnesota, Consortium Law & Values Hlth Environm & Life Sci, Sch Med, Sch Law, Minneapolis, MN 55455 USA
基金
美国国家卫生研究院;
关键词
Nanomedicine; Biomedical nanotechnology; Nanobiotechnology; Clinical trials; Human subjects research; GOLD NANOPARTICLES; PHASE-I; NANOCRYSTALLINE HYDROXYAPATITE; MAGNETIC NANOPARTICLES; NANOTECHNOLOGY; DELIVERY; SIZE; CANCER; PREVENTION; CHEMISTRY;
D O I
10.1016/j.nano.2012.05.013
中图分类号
TB3 [工程材料学];
学科分类号
082905 [生物质能源与材料];
摘要
Developments in nanomedicine are expected to provide solutions to many of modern medicine's unsolved problems, so it is no surprise that the literature contains many articles discussing the subject. However, existing reviews tend to focus on specific sectors of nanomedicine or to take a very forward-looking stance and fail to provide a complete perspective on the current landscape. This article provides a more comprehensive and contemporary inventory of nanomedicine products. A keyword search of literature, clinical trial registries, and the Web yielded 247 nanomedicine products that are approved or in various stages of clinical study. Specific information on each was gathered, so the overall field could be described based on various dimensions, including FDA classification, approval status, nanoscale size, treated condition, nanostructure, and others. In addition to documenting the many nanomedicine products already in use in humans, this study indentifies several interesting trends forecasting the future of nanomedicine. From the Clinical Editor: In this one of a kind review, the state of nanomedicine commercialization is discussed, concentrating only on nanomedicine-based developments and products that are either in clinical trials or have already been approved for use. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 119 条
[61]
Manomagnetic Drug Delivery, 2006, MAN DRUG DEL
[62]
Masse A, 2000, J BIOMED MATER RES, V53, P600, DOI 10.1002/1097-4636(200009)53:5<600::AID-JBM21>3.0.CO
[63]
2-D
[64]
Preclinical and clinical studies of anticancer agent-incorporating polymer micelles [J].
Matsumura, Yasuhiro ;
Kataoka, Kazunori .
CANCER SCIENCE, 2009, 100 (04) :572-579
[65]
Mebiopharm-Product & Technologies, 2011, MEB PROD TECHN
[66]
Morgan LR, 2006, CANCER CHEMOTH PHARM, V64, P829
[67]
Morse M, 2005, CURR OPIN MOL THER, V7, P164
[68]
Mraz S., NEW BUCKYBALL BOUNCE
[69]
NanoDxNanoparticles, 2010, NANODX NAN
[70]
Nanotechnology and medicine / Nanotechnology medical applications, 2011, NAN MED NAN MED APPL